Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to -$3.0 billion.

  • Apellis Pharmaceuticals' Retained Earnings changed 0.0% to -$3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 billion, marking a year-over-year change of 0.0%. This contributed to the annual value of -$3.0 billion for FY2024, which is 697.37% down from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Retained Earnings stood at -$3.0 billion, which was down 0.0% from -$3.2 billion recorded in Q2 2025.
  • Apellis Pharmaceuticals' Retained Earnings' 5-year high stood at -$1.1 billion during Q1 2021, with a 5-year trough of -$3.2 billion in Q2 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$2.6 billion (2023), whereas its average is -$2.4 billion.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Retained Earnings tumbled by 7884.1% in 2021, and later changed by 0.0% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Retained Earnings stood at -$1.7 billion in 2021, then crashed by 39.37% to -$2.3 billion in 2022, then dropped by 22.9% to -$2.8 billion in 2023, then dropped by 6.97% to -$3.0 billion in 2024, then grew by 1.17% to -$3.0 billion in 2025.
  • Its last three reported values are -$3.0 billion in Q3 2025, -$3.2 billion for Q2 2025, and -$3.1 billion during Q1 2025.